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Abstract
Background: Charcot Neuro-Arthropathy (CN) is one of the more devastating complications of diabetes. To the
best of the authors’ knowledge, it appears that no clinical tools based on a systematic review of existing literature
have been developed to manage acute CN. Thus, the aim of this paper was to systematically review existing
literature and develop an evidence-based clinical pathway for the assessment, diagnosis and management of acute
CN in patients with diabetes.
Methods: Electronic databases (Medline, PubMed, CINAHL, Embase and Cochrane Library), reference lists, and
relevant key websites were systematically searched for literature discussing the assessment, diagnosis and/or
management of acute CN published between 2002-2012. At least two independent investigators then quality rated
and graded the evidence of each included paper. Consistent recommendations emanating from the included
papers were then fashioned in a clinical pathway.
Results: The systematic search identified 267 manuscripts, of which 117 (44%) met the inclusion criteria for this
study. Most manuscripts discussing the assessment, diagnosis and/or management of acute CN constituted level IV
(case series) or EO (expert opinion) evidence. The included literature was used to develop an evidence-based
clinical pathway for the assessment, investigations, diagnosis and management of acute CN.
Conclusions: This research has assisted in developing a comprehensive, evidence-based clinical pathway to
promote consistent and optimal practice in the assessment, diagnosis and management of acute CN. The pathway
aims to support health professionals in making early diagnosis and providing appropriate immediate management
of acute CN, ultimately reducing its associated complications such as amputations and hospitalisations.
Keywords: Charcot Neuro-Arthropathy, Management, Clinical pathway, Diabetes
Background
Charcot Neuro-Arthropathy (CN) is one of the more dev-
astating complications affecting patients with diabetes and
peripheral neuropathy [1]. It is a progressive, destructive
condition that is characterised by acute fractures, disloca-
tions and joint destruction in the weight-bearing neuro-
pathic foot [2]. The acute phase is often misdiagnosed and
can rapidly lead to severe foot deformity, ulceration and
amputation [1,3,4]. Early diagnosis and management of
acute CN is therefore imperative to avoid the rapid pro-
gression towards permanent foot deformation and its as-
sociated complications [5].
There are many reported aetiologies of CN, however
in modern western societies diabetes mellitus has be-
come the leading cause [1,5-7]. The true prevalence of
CN is unknown, most likely due to a high incidence of
mistaken or delayed initial diagnosis [7], but a number
of population-based studies have reported an estimated
prevalence of 0.4-13% in patients with diabetes [7,8].
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To date, best practice assessment, diagnosis and man-
agement of acute CN appears to be influenced more by
expert consensus than a rigorous evidence-base [1,5,6].
This may be because acute CN is considered one of the
more rare complications of those caused by diabetes and
thus tends to fall outside of the existing national guidelines
or systematic reviews on diabetic foot complications [9].
This paper therefore aims to systematically review current
relevant literature and develop an evidence-based clinical
pathway for the assessment, diagnosis and management of
acute CN in patients with diabetes.
Methods
Search strategy
A systematic review of the most relevant CN literature
published between 2002-2012 was undertaken in the
process of developing the clinical pathway. The search
strategy was designed to identify relevant literature that fo-
cussed on the clinical assessment, diagnosis and/or conser-
vative management of acute CN. For the purpose of this
study the terms Charcot, Arthropathy, Neuroarthropathy,
Osteoarthropathy, Neuro-Osteoarthropathy, and Neuro-
genic-Arthropathy were used interchangeably. The subse-
quent clinical pathway was guided by the recommendations
specified by the National Health and Medical Research
Council of Australia (NHMRC), 1999 [10,11].
Electronic databases (Medline, PubMed, CINAHL,
Embase and Cochrane Library: Databases of Systematic
Reviews) were searched for relevant literature by the
first author in August 2012. Key search terms used were
Charcot, Arthropathy, Neuroarthropathy, Osteoarthropathy,
Neuro-Osteoarthropathy, and Neurogenic-Arthropathy. The
search strategies for each database are summarised in
Additional file 1. The exclusion criteria included papers
published prior to 2002, not written in English, non-diabetes
papers, or papers discussing the surgical management
only of acute CN. As the focus of this paper was pro-
viding a contemporary clinical pathway for non-
surgical health professionals, the authors considered
the last decade of publications to be appropriate and
to exclude surgical papers.
The initial search was intentionally broad in order to
identify all literature pertaining to CN, and thus included
both empirical evidence and expert opinion. To ensure
completeness, the first author hand searched the reference
lists of the initial manuscripts identified, searched web
pages of relevant diabetes organisations for clinical prac-
tice guidelines, and contacted local and international ex-
perts in the field in an effort to identify any literature that
may not have been identified in the initial search.
Study selection
All titles and abstracts retrieved by the initial search were
scanned by the first author using the following screening
question: Does the article discuss the clinical assessment,
diagnosis and/or conservative management of acute CN in
the diabetic foot? If the article was deemed to meet the
screening question, the first author retrieved the full text
for quality assessment by the co-authors.
Quality assessment
Co-authors, with expertise in diabetes related foot com-
plications (TM, JR, EK, HM, PL, TQ), reviewed all iden-
tified full texts. At least two blinded co-authors
independently reviewed each included article to assess
its relevance and quality, and grade its level of evidence
according to the NHMRC guidelines [9-11]. Table 1 pro-
vides definitions for the NHMRC levels of evidence
[9,10]. Firstly, co-authors were required to review the full
text to ensure it met all original inclusion criteria and to
specifically exclude articles that focussed only on surgi-
cal management of CN or CN in non-diabetes popula-
tions. Secondly, co-authors were asked to assess if the
article was of adequate quality or methodologically
sound. In consideration of the small amount of literature
published on CN, the definition of methodologically
sound was broadened to exclude only articles not
reporting methods or procedures (for example letters to
the editor or commentaries). Lastly, the co-authors rated
the article to assign it a level of evidence according to
NHMRC guidelines [10,11]. Any inconsistencies be-
tween the assessments of manuscripts were resolved by
the assessment of a third co-author.
Data extraction
Literature that met the final inclusion criteria was then
used to construct the clinical pathway. In an attempt to
aid clinical management, the authors decided to base the
development and flow of the pathway on the clinical
phases evident in current general clinical management.
These phases include assessments, investigations, diag-
nosis and management. Any common recommendations
emanating from the final literature search were identi-
fied by the first and second authors and entered into
the clinical domains. Clinical recommendations on the
pathway were also welcomed from experts where quality
evidence was lacking. The recommendations were
prioritised according to level of evidence and relevance
to the clinical pathway (Additional file 2, Additional
file 3, Additional file 4). The final pathway was agreed to
by the consensus of all co-authors.
Results
A total of 267 manuscripts were identified from the ini-
tial search strategy. Of these, 117 (44%) were assessed to
meet the final inclusion criteria and were used in the de-
velopment of the clinical pathway. The 150 (56%) arti-
cles excluded were either considered lacking in quality
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or did not meet the final inclusion criteria. The large
majority of manuscripts included were either expert
opinion (67.5%) or level IV evidence (19%). Only three
level II randomised control studies (RCT’s) were identi-
fied. Table 2 summarises the evidence levels of all in-
cluded manuscripts. Table 3 summarises the country of
publication origin of all included manuscripts. Most
manuscripts were published in either the USA (50%) or
UK (26%).
The pathway is divided into the four key phases for
the clinical management of acute CN that have been
addressed by the included literature. These phases are 1)
Assessment, 2) Investigations, 3) Diagnosis, and 4) Man-
agement of acute CN. Unfortunately, some areas
pertaining to these phases of management are devoid of
quality research and in these instances low-level evi-
dence, such as expert opinion, was utilised. The clinical
pathway is presented in Figure 1.
Assessment
Clinical signs & symptoms
Localised unilateral swelling, erythema, warmth, +/−
pain (50%), +/− deformity: level of evidence = IV It is
well reported that acute CN characteristically presents
with localised swelling, erythema and increased temp-
erature (>2°C compared to the contralateral foot) to the
affected foot [1,3,12,13]. Owing to the presence of per-
ipheral neuropathy, pain may not always be present (re-
portedly in only 50% of cases) or will be less than
expected given the severity of the clinical findings
[12,14,15]. The diagnosis of acute CN is primarily de-
pendant on this initial clinical presentation and therefore
requires high clinical suspicion by the treating clinician
for all patients with diabetes and peripheral neuropathy
who present with these clinical signs and symptoms
[14]. More advanced presentations of acute CN may also
present with obvious foot deformity, including the char-
acteristic ‘rocker-bottom’ deformity that is emblematic
of CN [16].
Urgent referral to multidisciplinary high risk foot
service: level of evidence = EO If acute CN is suspected,
an urgent referral to a multidisciplinary high-risk foot
service or specialist clinic is recommended for appropri-
ate multidisciplinary management of this complex condi-
tion [9,11,12,17,18].
Clinical assessments
History of trauma (25-50%): level of evidence = III-2
or recent surgery: level of evidence = IV Preceding
trauma may be recalled in as many as half of all cases of
acute CN (25-50%) [3,15,16,19-22]. The role of trauma
Table 1 NHMRC levels of evidence
Level of
evidence
Definition
I A systematic review of level II studies
II A randomised controlled trial
III A pseudorandomised controlled trial (i.e. alternate allocation or some other method)
III-2 A comparative study with concurrent controls (i.e. non-randomised experimental trial, cohort study, case–control study)
III-3 A comparative study without concurrent controls (i.e. historical cohort study, two or more single arm study)
IV Case series
EO Expert opinion – where evidence was absent or unreliable and advice was formulated based on the clinical judgement and
experience of experts in the field
Table 2 Evidence levels of included manuscripts
Level of evidence Included manuscripts (117)
I 0.0% (0)
II 2.5% (3)
III 11.0% (13)
IV 19.0% (22)
EO 67.5% (79)
Table 3 Country of publication of included manuscripts
Country of publication Included manuscripts (117)
USA 50% (58)
UK 26% (31)
Germany 7% (8)
Netherlands 6% (7)
Israel 2% (2)
Scandinavia 2% (2)
Australia 1% (1)
Canada 1% (1)
China 1% (1)
France 1% (1)
Hong Kong 1% (1)
India 1% (1)
Morocco 1% (1)
Sweden 1% (1)
Switzerland 1% (1)
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in an insensate extremity has been reported as an im-
portant factor in the pathogenesis of acute CN and
should therefore be queried at the initial presentation
[15,21]. However, due to the presence of an insensate ex-
tremity, it is important to consider recall bias as a
cofounding factor and therefore a history of trauma may
be unreliable [1]. In incidences where no trauma is
recalled, repetitive micro-trauma on an insensate foot
may be a contributing factor [9,21,22].
Recent foot surgery has also been described as a pos-
sible precipitating factor to acute CN [3,23]. The precise
mechanisms by which surgery affects the pathogenesis
of CN remain unclear, however it is reported that it may
be associated with the local inflammation following
surgery or alternatively as a result of the foot deform-
ity following pedal amputation [1,24]. Pedal amputa-
tion can functionally compromise the foot leading to
altered weight bearing forces that result in repetitive
micro-trauma, a reported precipitating factor of acute
CN [25,26].
Long-standing diabetes: level of evidence = II The re-
lationship between duration of diabetes and the onset of
acute CN is well reported in a number of clinical trials
and case series. Most commonly, at the time of onset pa-
tients with both Type 1 or Type 2 diabetes have been di-
agnosed for a period >10 years [8,13,27-30].
Peripheral neuropathy: level of evidence = III The
presence of peripheral sensory neuropathy is an important
component for the onset of acute CN with no reported
cases developing in its absence [1,8,31,32]. Peripheral sen-
sory neuropathy can be accurately assessed using the
Semmes-Weinstein 10 g monofilament [8,9,11,16,32].
Normal peripheral arterial perfusion: level of evidence-
III Generally, the acute CN foot has well preserved ar-
terial perfusion. Pedal pulses can be palpated and are
often described as ‘bounding’ in the acute CN foot, un-
less obscured by associated swelling. In this instance, the
use of a doppler ultrasound may be required to assess
arterial perfusion [1,8,9,11,31].
Infrared dermal thermometry comparisons >2°C:
level of evidence = IV Given the local inflammatory re-
sponse during the acute phase of CN, temperature mon-
itoring with the use of a handheld infrared dermal
thermometre is a useful diagnostic assessment tool
[33,34]. Infrared dermal thermometry comparisons be-
tween contralateral corresponding locations are typically
>2.0°C in the affected foot [21,35,36]. Temperatures
should be assessed approximately 15 minutes after the
cast and footwear is removed and the use of an infrared
dermal thermometer precise to ±0.1°C for a more
Figure 1 Acute Charcot Pathway of Clinical Care.
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accurate assessment is recommended [37]. Due to an ab-
sence of studies objectively determining or comparing
different sites for temperature assessment, recommenda-
tions vary amongst the literature. Most frequently, how-
ever, skin temperatures are measured at the following 9
sites: dorsal mid foot, hallux, medial 1st metatarsal head,
plantar 3rd metatarsal head, lateral 5th metatarsal head,
1st metatarsal-cuneiform joint, talonavicular joint, cu-
boid, plantar heel, and ankle [33,37].
Immediate clinical management
Immediate immobilisation: level of evidence = IV In
order to reduce the risk of severe chronic deformity, if
acute CN is suspected, immediate immobilsation should
be implemented until a definitive diagnosis is deter-
mined [12,38-40]. Immobilisation remains the corner-
stone therapy for acute CN and is essential to break the
cycle of repetitive trauma propagating the acute phase
and to ultimately prevent the progression of deformity
[1,41,42]. Options for immobilsation include the total
contact cast and irremovable/removable walkers.
Total contact casts and irremovable walkers: level of
evidence = IV Total contact casts (TCCs) were origin-
ally referred to as the ‘gold standard’ immobilsation ther-
apy for acute CN, due to their custom and irremovable
nature [43-46]. The TCC is a custom moulded cast,
commonly using plaster of Paris or fibreglass, which
maintains contact with the entire planter service of the
foot and lower limb [43-46]. The TCC immobilises the
affected foot and ankle, reduces plantar foot pressures
and swelling, protects from additional trauma, and
maintains patient mobility [42,47].
An alternative to the TCC is the instant total contact
cast (iTCC) which has been reported to be just as effect-
ive in immobilising the acute CN foot, as well as being
more cost effective and requiring less skill to apply
[1,48]. An iTCC consists of a prefabricated removable
walker that is rendered irremovable by simply applying a
layer of tape or fibreglass cast roll around the body of
the walker to encourage patient compliance [2,46].
Removable walkers: level of evidence = IV Prefabricated
removable cast walkers have the benefit of immediate
application without specialist skills and have been
reported to be just as effective in offloading the diabetic
foot, however patient adherence is often significantly
reduced with these devices [31,41,47,48]. A large
observational study of 288 patients with acute CN,
reported that the use of irremovable offloading (TCC or
iTCC) shortened the median time to resolution by ap-
proximately 3 months when compared with removable
walkers [3]. This study highlights the issue with patient
adherence when removable devices are prescribed. As a
result, removable walkers should only be prescribed
when TCCs or iTCCs are deemed inappropriate.
Previous studies have advocated complete non-weight
bearing immobilsation with the use of crutches through
the initial acute phase, however it has been reported that
a three-point gait may in fact increase the load on the
contralateral foot and thereby predispose the patient to
bilateral acute CN [1,2,43]. Two recent case series dem-
onstrated that ambulatory casting during the acute phase
of CN does not negatively impact the outcome of CN
and may in fact reduce the loss of muscle tone and bone
density during immobilsation [1,42,44]. Given the pau-
city of empirical evidence regarding this issue, it is
recommended that protective weight bearing should be
advised at the discretion of the treating clinician.
Immobilisation considerations: level of evidence = IV
There are a number of important factors to consider
before prescribing the most appropriate immobilsation
device for the individual patient. The benefits of the
TCC may be limited by the need for specially trained cli-
nicians, available clinical time for application and prod-
uct cost. In addition, cast changes are required within
the first 3 days for the initial cast and 1-2 weekly there-
after to maintain proper fit and where necessary, permit
wound management [1]. These frequent reviews may
be particularly problematic for patients who live in rural
or underserviced communities that are distant from
specialised diabetic foot care clinics. In contrast, patients
with current foot deformity may be at risk of secondary
ulceration if fitted to a prefabricated walker and there-
fore a TCC may be the only appropriate means of
immobilsation. Lastly, patients with CN often have in-
creased instability and are at risk of falls as a result of
multiple co-morbidities, including loss of proprioception
and postural hypertension, and therefore aggressive cast
immobilsation may not be appropriate and alterative
modalities may need to be considered, such as a wheel-
chair [1,15,47].
Investigations
Imaging referrals
Plain weight bearing radiographs: level of evidence =
IV If a patient presents with localised unilateral swelling,
erythema and increased temperature in an insensate
foot, plain radiographs are an important first line investi-
gation and can be invaluable in ascertaining the presence
of CN. In most cases, no further imaging studies are re-
quired to confirm diagnosis [1,2]. Characteristic radio-
graphic signs of acute CN include bony consolidation,
fragmentation of subchondral bone, fractures, disloca-
tions, subluxations, osteopenia and osteolysis [35,49,50].
Although controversial, weight-bearing radiographs
without immobilsation can be valuable in identifying
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subtle fractures, fragmentations and joint subluxation
seen in very early stages of acute CN, which may not be
present on standard non-weight bearing films. Addition-
ally, joint deformity or collapse is often more accurately
assessed in weight bearing views, and therefore weight-
bearing views should be considered at the discretion of
the clinician [21,39,44,50].
Where clinical diagnosis remains inconclusive at
this time, further diagnostic investigations may be re-
quired to establish a diagnosis and exclude other pos-
sible causes.
Repeat radiographs at 2 weeks: level of evidence = EO
Normal radiographs at presentation does not necessarily
exclude CN and it therefore may be important to per-
form further imaging investigations to confirm the diag-
nosis [15,49]. Easily available and inexpensive, repeat
radiographs can be a valuable tool in confirming in the
final diagnosis, especially in more remote locations
where other diagnostic imaging modalities are not avail-
able. Repeat x-rays are generally obtained after 2 weeks
of the initial investigation as the radiographic signs of
acute CN generally become more conspicuous during
this period [33,34].
Magnetic resonance imaging: level of evidence = III
Magnetic resonance imaging (MRI) represents a non-
invasive and sensitive diagnostic tool in the study of
bone marrow and soft tissue abnormalities, providing
high quality images of the foot [51]. MRI has the ability
to detect subtle changes in the early stages of acute CN,
such as bone marrow oedema, before they are evident
on plain radiographs [1,51,52]. This can play an import-
ant role in the early diagnosis of acute CN, when radio-
graphs are inconclusive, thereby improving clinical
outcomes [51,52]. MRI has also been reported to be
both sensitive (77-100%) and specific (80%-100%) in the
diagnosis of CN and osteomyelitis, a well reported chal-
lenge for most treating clinicians [1,11,49,53]. Where
available and appropriate for use, MRI should be the im-
aging modality of choice for the diagnosis of acute CN
when radiographs are inconclusive [1,9,11,33].
Nuclear medicine: level of evidence = IV Nuclear
medicine includes a number of diagnostic tests based on
the use of radioisotopic tracers [1]. Nuclear medicine
may play an important role in the diagnosis of acute CN
where other imaging modalities, such as MRI, are con-
traindicated or unavailable [51]. Three-phase bone scans
are highly sensitive (<100%) to acute bone pathology but
lack specificity for acute CN [49,51]. For patients with
low clinical suspicion of osteomyelitis and no signs of
CN on initial radiographs, three-phase bone scans have
proven to be a useful tool in assisting in the diagnosis.
Alternatively, leukocyte-labelled bone or marrow scans
(99 m Tc HMPAO or 111 Indium) provide improved
specificity (69-80%) for distinguishing infection from
acute CN and are a more appropriate imaging tool when
underlying infection is suspected [1,8,18,49].
FDG-PET: level of evidence = IV More recently, 18
F-fluorodeoxyglucose positron emission tomography
(FDG-PET) has been recognised as having potential for
differentiating acute CN from osteomyelitis [1,49]. A few
recent studies have reported that combined FDG-PET
may have several advantages over existing imaging tech-
niques for diagnosing osteomyelitis and acute CN, in-
cluding improved sensitivity (100%) and specificity
(93.8%) for acute CN, high-quality images with de-
tailed anatomic localisation, and fast results within 1.5
to 2 hours after the initiation of the examination
[54-56]. However, the 2011 international task force
consensus document on the Charcot foot in diabetes
recommends that FDG-PET for the potential diagnosis
of acute CN and osteomyelitis remains investigational
at this time [1].
Bone biopsy: level of evidence = EO Bone biopsy re-
mains the only diagnostic method for definitive discrim-
ination between osteomyelitis and CN. This is not,
however, always appropriate and can potentially result in
a number of secondary complications including infec-
tion, excessive bleeding, pain, fracture, or new onset of
acute CN [53,57,58]. With these limitations in mind,
bone biopsy should only performed if the diagnosis re-
mains inconclusive after imaging is exhausted, or if
osteomyelitis is likely [53].
Serology referrals
There is currently no universally accepted serology cri-
terion for the diagnosis of CN; however, some studies
have reported that serology markers may assist in
narrowing the diagnosis [8,11,14,15,35,39,59].
Leukocytosis, C-reactive protein, and erythrocyte sedi-
mentation rate: level of evidence = IV Leukocytosis
(WCC), an elevated C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR), and recent unex-
plained hyperglycemia are all systemic responses to in-
fection [11,14,39]. The utility of these inflammatory
parameters for identifying infection has been supported
throughout the literature and could therefore be a valu-
able assessment tool for differentiating between acute
CN and infection [8,15,35,59]. Recent studies have dem-
onstrated that there is dissociation between the local
and systemic inflammatory response in acute CN, with
serum WCC, CRP, and ESR values remaining within the
reference range for patients with acute CN despite the
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presence of local inflammation [35,59]. Therefore, in the
absence of elevated systematic inflammatory markers,
infection may be an unlikely diagnosis and acute CN
should be considered [21].
Glycosylated haemoglobin: level of evidence = IV
Chronic hyperglycaemia is a major incipient factor in the
development of CN, a theory well supported by the litera-
ture [60]. One recent case study, reported that an elevated
glycosylated haemoglobin (HbA1c) is associated with
more than a 30% increase in the risk for developing CN
[61]. As mentioned earlier, recent unexplained hypergly-
caemia may also assist in the diagnosis of infection [14].
Clinicians have long recognised the importance of tight
glycaemic control in reducing the risk of diabetic foot
complications [61]. Therefore, as part of a multidisciplin-
ary approach to the management of a patient with diabetes
and suspected CN, it is recommended the HbA1c be
assessed and, where necessary, optimised [2].
Electrolytes and renal function: level of evidence = IV
Diabetic nephropathy has been reported to be associated
with an increased incidence of acute CN [28]. One case
study reported that renal failure nearly doubled the risk
of CN (OR 2.1, p < 0.001), suggesting that patients with
co-existing renal failure be carefully monitored for signs
of acute CN [61].
Calcium and vitamin D: level of evidence = EO Patho-
logical or traumatic fractures are a reported misdiag-
nosis of acute CN, often associated with deficiencies
in calcium and vitamin D resulting in inadequate min-
eralisation of the bone [1,59,62]. Furthermore, if
bisphosphonates are administered as part of the man-
agement plan, they require adequate levels of calcium
and vitamin D to work effectively [6,63,64]. Therefore,
investigating calcium and vitamin D levels may be benefi-
cial in assisting with the diagnosis and/or directing the
management plan.
Uric acid: level of evidence = EO An acute gout attack
may also masquerade as acute CN, however can be ex-
cluded by measurement of serum uric acid, which is typ-
ically raised in the presence of gout [15,39,65].
Diagnosis
Acute CN diagnosis criteria
Level of evidence = IV In the absence of rigorous evi-
dence, the most commonly accepted criteria by treating
clinicians for the diagnosis of acute CN is: a warm, swol-
len, erythematic foot (clinical signs), with or without any
significant history of trauma or surgery, a temperature
difference from the contralateral foot of > 2°C, and
conclusive diagnostic images suggestive of acute CN
[1,13,29,55]. In the presence of a wound or history of
osteomyelitis, clinical suspicion and assessment of osteo-
myelitis should be considered [2,11,12,16].
Negative diagnosis
Level of evidence = EO In the event that CN may not
be the most likely diagnosis, experts in the field recom-
mend continuing with immobilisation until a definitive
diagnosis is made so that the risk of foot deformity or
other associated complications can be avoided if in fact
CN is later diagnosed [4,38].
Differential diagnosis
Level of evidence = III-2 Historically, misdiagnoses for
acute CN have included infection (osteomyelitis, cellu-
litis, abscess, deep tissue infection), DVT, acute gout,
neuropathic/traumatic fractures, sprain, or inflamma-
tory arthritis [4,17,21,22,59]. One retrospective case
series reported that 80% of patients with acute CN
were initially misdiagnosed as having sprains (n = 11),
DVT (n = 3), osteomyelitis (n = 4), tumour (3), cellulitis
(n = 6), or rheumatoid arthritis (n = 2) [17]. Given its
rare presentation, it is not surprising that a large num-
ber of cases of acute CN are initially misdiagnosed; how-
ever, this only further emphasises the need for high
clinical suspicion when a patient with diabetes and neur-
opathy presents with the clinical signs and symptoms sug-
gestive of acute CN.
Management
Acute management
Continue immobilisation: level of evidence = IV
Immobilsation of the affected foot continues until complete
resolution of the acute phase [3,31,42]. The cast is initially
replaced (TCC) or re-fit (iTCC, removable walker) after the
first 3 days due to the significant oedema reduction seen
after this period. The cast is then replaced 1-2 weekly after
this time, again to adjust for limb volume changes from
oedema and to assess for any complications secondary to
immobilsation [1,43].
Education: level of evidence = EO Patient education
regarding the diagnosis, estimated length of treatment
and expected outcomes is an important component of
CN management. If the patient understands the nature
of this limb-threatening condition, they may be more
motivated to adhere to the management plan. Emphasis
on the importance of strict immobilisation, attending
regular follow-up reviews and optimising glucose control
may improve the outcome of CN [11,39,58,66].
Appropriate contralateral footwear: level of evidence =
IV Bilateral CN is reported in as many as 30% of cases
[8,45,67]. As stated earlier, immobilsation therapy,
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especially with the use of crutches, has been reported to
potentially increase the load on the contralateral foot
and thereby predispose the patient to bilateral acute CN
[1,2]. For this reason, prophylactic support with appropri-
ate footwear and accommodative insoles is recommended
for the contralateral foot to minimise the risk of bilateral
acute CN [9,39,68,69].
Oedema control: level of evidence = EO When a TCC
is applied to immobilise the acute CN, the compression
of the cast will assist in reducing the oedema present in
the acute phase. However, when a prefabricated walker
is used it is recommended that oedema be managed with
alternative compression therapies such as elastic banda-
ging [31,70].
Regular reviews: level of evidence = IV During the im-
mobilisation period, regular reviews by a high-risk foot
service are important to monitor the activity of the acute
phase, review the management plan, and assess and
manage any secondary complications [1]. Measuring
skin temperature differences between the affected
and the non-affected foot using an infrared dermal
thermometre is an objective measure for monitoring re-
duction in inflammation during the acute phase of CN
[21,34,66]. The literature suggests that elevated tempera-
tures will correlate with the location of CN and that
temperatures in the affected foot will decrease as acute
CN progresses into the chronic phase [33]. TCC’s should
be re-casted and the fit of walkers re-assessed at 1-2
weekly reviews to adjust to limb volume changes as the
oedema subsides during immobilisation [2,43,44,71].
Periodic follow-up radiographs: level of evidence = EO
Following the initial diagnosis, follow-up radiographs
of the affected foot every 4-6 weeks will monitor the
progression of CN, as well as any changes in the ar-
chitectural alignment and configuration of the foot
[8,33,34,42,70]. However, given the paucity of empirical
evidence recommending the benefit of periodic follow-
up radiographs, these are performed at the discretion of
the treating clinician.
Appropriate referrals: level of evidence = EO Given
the complexity of CN, a multidisciplinary approach to
the holistic management of the patient is recommended
[72]. Where appropriate, the authors recommend
referrals to a multidisciplinary high-risk foot clinic
[12,17,39], local general practitioner or specialist phys-
ician to optimise diabetes management and/or other
relevant comorbidities [61,64,66,73], and occupational
therapy for a home environment assessment, especially
when crutches or a wheel chair are prescribed [15].
Bisphosphonates: level of evidence = II There are cur-
rently conflicting reports on the clinical benefits of
bisphosphonates for the management of acute CN [6].
Systematic reviews of clinical trials have indicated that
bisphosphonates are ineffective and may even be harm-
ful to the resolution time of the acute phase of CN
[3,6,13]. In contrast, other studies of the same level
of evidence have supported their use, suggesting that
bisphosphonates may improve the resolution time of
the acute phase by reducing skin temperature and dis-
ease activity [72,74-76]. Therefore, given the inconclu-
sive evidence on their use, it is recommended that
bisphosphonates be used at the discretion of the treating
physician for cases of acute CN that are non-responsive
to conservative immobilsation management.
Average management time: level of evidence = II A
number of clinical trials and case series have reported
average management times for the complete resolution
of CN between 2-12 months, with a period of 6 months
being most commonly reported [3,13,17,27,28,31,42,47].
The literature suggests that the management time
may be influenced by the location of CN, type of
immobilsation used, and the stage of CN when immobil-
isation is implemented [3,17,20,39,47].
Chronic CN diagnosis criteria
Level of evidence = IV The duration of immobilisation is
guided by the clinical assessment that the acute phase has
completely resolved [1]. This is evident by the resolution
of all clinical signs and symptoms, stabilised contralateral
skin temperatures, and evidence of healing on radiographs
[13,31]. Previous studies have recommended a skin
temperature difference between contralateral locations of
<2°C for 2-4 consecutive weeks before transitioning pa-
tients from cast immobilisation to a removable walker or
appropriate footwear [21,31-33]. Radiographs are an im-
portant tool in assisting in the diagnosis of chronic CN
and are recommended once all clinical signs and symp-
toms have resolved [49]. Radiographic evidence of chronic
CN includes healed fractures, sclerosis of bone, absorption
of bony debris, fusion and rounding of large fragments,
and increased bone density [15,49,68,76]. Feet with severe
CN deformity are siginificantly associated with midfoot ul-
ceration. Therefore, weight bearing radiographs of chronic
CN may be more beneficial at this time to assess the pres-
ence and degree of deformity so that appropriate long
term offloading can be prescribed [77].
Long-term management
Partial weight bearing: level of evidence = IV Once
the foot is stable, transition to protected weight bearing
is generally advised before the patient steps down to
footwear [2,30,66]. Aircast walkers or other similar
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prefabricated removable walkers have gained acceptance
as useful protective modalities for this initial period of
weight bearing [15,44,66]. Partial weight bearing has
been reported to minimise the risk of reactivation of the
acute phase if immobilsation is ceased too early [20,31].
Footwear and offloading: level of evidence = IV Foot-
wear is an important component of the long-term man-
agement of the insensate chronic CN foot, ensuring that
it remains accommodated, offloaded and protected.
In patients with nil to minor foot deformity after the
resolution of acute CN, prefabricated footwear with extra
depth and a stiff rocker bottom walking sole may suffice.
These shoes, when fitted with custom-molded, full-
contact insoles, will adequately minimise load bearing and
mobility of the foot during walking [2,8,20,30,44,47].
In the presence of moderate deformity, custom-made
or modified shoes are generally necessary to accommo-
date the chronic foot deformity. Again, these shoes
should be fitted with custom-molded, full contact insoles
to minimise load bearing and mobility during walking
[8,20,78].
Chronic CN that has resulted in severe foot deform-
ities and/or CN that is located in the ankle or rear foot
(location IV or V) can often be difficult to stabilise with
footwear and typically requires more aggressive long
term management such as a Charcot Restraint Orthotic
Walker (CROW) to achieve stability and reduce the risk
of reactivating the acute phase [1,15,40,46]. The CROW
has proven to be useful in maintaining foot and ankle
alignment in the instable or surgical corrected CN foot
[78], however, where aggressive conservative manage-
ment has failed, surgical correction of the deformity
should be considered [1].
Education: level of evidence = EO Patient education
should form an essential component of the long-term
management of these patients, focusing on the import-
ance of appropriate footwear and offloading, regular fol-
low up reviews, and the risk of further complications
[11,12,66].
Rehabilitation: level of evidence = EO Following an ex-
tended period of immobilsation, there will likely be wast-
ing of the calf muscles, loss of bone density and joint
stiffness [42,44]. Protective rehabilitation with a physio-
therapist is recommended following the transition phase
out of immobilisation, being cautious, however, of the
risk of reactivation of the acute phase or ulceration of
bony deformity by excessive rapid mobilisation during
the early stages of rehabilitation [15,37].
Long term follow up and/or reactivation: level of evi-
dence = IV Three monthly podiatry reviews of these
high-risk patients is advised to monitor for signs of re-
current or new episodes of CN, as well as any other dia-
betic foot complications [1,9,12,15]. Recurrence is
reported in 15-30% of patients with a previous history of
CN [3,15,69,79].
Surgical: level of evidence = IV Typically, if the correct
diagnosis is made in the acute phase of CN and conser-
vative treatment is successful, surgery may be avoided
and the risk of subsequent ulcerations and/or amputa-
tion may be decreased [30]. Surgical management is usu-
ally only considered in the chronic phase of CN where
joint instability and/or severe deformity have failed to
be effectively managed with a conservative approach
[1,2,30]. Up to 50% of patients have been reported to
undergo surgical procedures for long-term management
of CN deformities and instabilities, most commonly oc-
curring 4 years after the initial acute phase [2,30]. Surgery
is generally avoided during the acute phase of CN due to
the risk of mechanical failure or secondary infection [1].
Discussion
Our systematic search of relevant literature highlights
that CN continues to be a poorly understood disorder
of the diabetic foot. Although recent clinical research has
improved our level of knowledge regarding its etiology
and management, there are still only a few high-level
evidence-based studies regarding the assessment, diagno-
sis and management of acute CN [39]. As hypothesised,
most literature pertaining to this field constitutes level IV
or EO evidence and no systematic reviews were identified.
Thus, this review begins to fill a gap commonly found in
Australian and international diabetic foot complication
guidelines that overlook the systematic review of CN [9].
CN continues to be a persistent challenge for clini-
cians, especially in its acute phase [6]. The literature re-
ports that the diagnosis of CN is missed in as many as
79% of cases and an accurate diagnosis can be delayed
up to 29 weeks. This highlights a clear gap in profes-
sional education, which this pathway hopes to address
[4,21]. Moreover, it is well reported that patients with
CN experience increased morbidity and mortality, a
higher risk of amputations, and a reduced quality of life
[5,6,30].
Currently, most available clinical guidelines on the
management of acute CN are without a rigorous evidence-
base, as displayed in the current pathway [2,18,80]. There-
fore in the era of evidence-based medicine, this research
has assisted in developing a comprehensive, evidence-
based clinical pathway designed to promote consistent and
optimal practice in the assessment, diagnosis and manage-
ment of acute CN. However, it should be noted that
whilst the pathway is there to assist clinician evidence
based decision-making, clinical discretion is still very
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much required especially with the low level of evi-
dence that most recommendations in this pathway
carry.
A number of strengths and limitations of the review
need to be acknowledged. Our review was deliberately
broad and, given the paucity of methodologically rigor-
ous studies in the field, included a review of expert opin-
ion in order to provide a comprehensive basis for
development of the pathway. All identified manuscripts
were reviewed for relevance and quality by at least two
members of the expert panel of podiatrists. However,
this was done without the use of a formal quality ap-
praisal tool and therefore the process was not validated.
High-level evidence was prioritised in the development
of the pathway, however, where evidence was lacking,
expert opinion was sometimes the only option. In this
case, it should be acknowledged that the recommenda-
tion is based on expert opinion rather than scientific evi-
dence and this should be reviewed as new evidence
becomes available [9]. Only studies published in English
between 2002-2012 were included and it is therefore
possible that some relevant research was excluded. How-
ever, hand searching of reference lists, exploration of
grey literature and websites, and consultation with local
and international researchers is likely to have minimised
this possibility.
The authors recommended that the clinical pathway
be now tested for validity & reliability, and used in larger
longitudinal studies to investigate its impact on the dev-
astating clinical outcomes of acute CN.
Conclusions
CN appears to be a significantly under-recognised and
under-researched complication of diabetes. Whilst CN
remains a rare complication of diabetes, it results in sig-
nificant levels of morbidity and mortality in the popula-
tion of people with diabetes. Thus, immediate best
practice management of this devastating complication is
vital to improve clinical outcomes and patient quality of
life. This systematic review, and subsequent pathway
development, appears to be one of the first in the area
of CN management. The pathway aims to support health
professionals in making early diagnosis and providing
appropriate immediate management of acute CN, ultimately
preventing and reducing its associated complications such
as amputations and hospitalisations. It is recommended that
the pathway’s clinical outcomes are implemented and fur-
ther researched to determine its applicability to minimise
the devastating effects of CN.
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